199 related articles for article (PubMed ID: 20514540)
1. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.
Heller A; Zörnig I; Müller T; Giorgadze K; Frei C; Giese T; Bergmann F; Schmidt J; Werner J; Buchler MW; Jaeger D; Giese NA
Cancer Immunol Immunother; 2010 Sep; 59(9):1389-400. PubMed ID: 20514540
[TBL] [Abstract][Full Text] [Related]
2. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study.
Bracci PM; Zhou M; Young S; Wiemels J
Cancer; 2012 Nov; 118(21):5384-94. PubMed ID: 22517435
[TBL] [Abstract][Full Text] [Related]
3. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
4. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
5. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
[TBL] [Abstract][Full Text] [Related]
6. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
[TBL] [Abstract][Full Text] [Related]
7. Profiling of autoantibodies in sera of pancreatic cancer patients.
Nagayoshi Y; Nakamura M; Matsuoka K; Ohtsuka T; Mori Y; Kono H; Aso T; Ideno N; Takahata S; Ryo A; Takeda H; Ito T; Oda Y; Endo Y; Sawasaki T; Tanaka M
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S459-65. PubMed ID: 24585405
[TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
Nakatsura T; Senju S; Ito M; Nishimura Y; Itoh K
Eur J Immunol; 2002 Mar; 32(3):826-36. PubMed ID: 11870627
[TBL] [Abstract][Full Text] [Related]
9. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.
Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM
Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361
[TBL] [Abstract][Full Text] [Related]
10. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma.
Meng Z; Ren D; Zhang K; Zhao J; Jin X; Wu H
Aging (Albany NY); 2020 Mar; 12(6):5048-5070. PubMed ID: 32181755
[TBL] [Abstract][Full Text] [Related]
11. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer.
Nakatsura T; Senju S; Yamada K; Jotsuka T; Ogawa M; Nishimura Y
Biochem Biophys Res Commun; 2001 Mar; 281(4):936-44. PubMed ID: 11237751
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of molecular biologogy and immunologic parameters in human pancreatic carcinoma].
Gansauge F; Gansauge S; Müller J; Schmid E; Beger HG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):69-72. PubMed ID: 14518215
[TBL] [Abstract][Full Text] [Related]
13. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus.
Syrigos KN; Konstantoulakis MM; Fyssas I; Katsilambros N; Golematis BC
Int J Cancer; 1996 May; 66(5):624-6. PubMed ID: 8647623
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis.
Wang Y; Wang P; Liu M; Zhang X; Si Q; Yang T; Ye H; Song C; Shi J; Wang K; Wang X; Zhang J; Dai L
J Immunol Methods; 2021 May; 492():112991. PubMed ID: 33587914
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin is a B cell molecular target in some gastrointestinal malignancies.
Pekáriková A; Sánchez D; Palová-Jelínková L; Simsová M; Benes Z; Hoffmanová I; Drastich P; Janatková I; Mothes T; Tlaskalová-Hogenová H; Tucková L
Clin Exp Immunol; 2010 May; 160(2):215-22. PubMed ID: 20030668
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.
Moniaux N; Chakraborty S; Yalniz M; Gonzalez J; Shostrom VK; Standop J; Lele SM; Ouellette M; Pour PM; Sasson AR; Brand RE; Hollingsworth MA; Jain M; Batra SK
Br J Cancer; 2008 May; 98(9):1540-7. PubMed ID: 18392050
[TBL] [Abstract][Full Text] [Related]
18. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.
Satomura Y; Sawabu N; Takemori Y; Ohta H; Watanabe H; Okai T; Watanabe K; Matsuno H; Konishi F
Pancreas; 1991 Jul; 6(4):448-58. PubMed ID: 1678888
[TBL] [Abstract][Full Text] [Related]
19. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
20. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma.
Chu KU; Ravindranath MH; Gonzales A; Nishimoto K; Tam WY; Soh D; Bilchik A; Katopodis N; Morton DL
Cancer; 2000 Apr; 88(8):1828-36. PubMed ID: 10760759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
